Vascular Medicine News

People who did not adhere to a long-term aspirin regimen after an MI had a higher risk for recurrent MI, stroke or death, although the risk appeared less pronounced among older adults and women, according to study results.

Esperion Therapeutics announced the FDA approved broad label expansion for bempedoic acid and bempedoic acid/ezetimibe for CV risk reduction and LDL lowering in both primary and secondary prevention populations.

More than 20% of reported cases of adverse events following bispecific T-cell engager therapies involved a cardiovascular event, findings reported in Journal for ImmunoTherapy of Cancer showed.

In patients with heart failure or coronary artery disease who also had anxiety and/or depression, treatment for their mental health condition was linked to better clinical outcomes, researchers reported.

Abiomed has issued a recall of the instructions for use for its left-sided blood pumps, as the pump catheter may perforate the wall of the left ventricle or cause free wall rupture, hypertension, lack of blood flow or death.

Idorsia announced that the FDA has approved aprocitentan, its antihypertensive drug, for treatment of hypertension in combination with other drugs in patients whose BP is not adequately controlled on other drugs.

Among patients who died of acute respiratory distress syndrome associated with SARS-CoV-2, the virus that causes COVID-19, heart tissues were damaged even when they were not directly affected by the virus, researchers reported.

Researchers in Kentucky identified mechanisms by which heat exposure caused immune response that may increase inflammation.

The nature of the relationship between discrimination, smoking and features of CVD is complex and varies by race and sex, according to a moderated mediation analysis published in the Journal of the American Heart Association.

An op-ed published in February by Tom Frieden, MD, MPH, former director of the CDC, described hypertension as “the deadliest but most neglected and widespread pandemic of our time” — and he’s right.